Briefing
ADAPT-MRD: ctDNA-guided adjuvant therapy after resection of pancreatic cancer
Randomized trial comparing ctDNA-guided adjuvant therapy with standard adjuvant therapy after radical resection of pancreatic cancer. ClinicalTrials.gov lists the study as recruiting, with a start date of June 1, 2025.
- Design: Not specified · Recruiting